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Introduction. The association of bone morphogenetic protein 2 (BMP2) with BMD and risk of fracture was suggested by a recent
linkage study, but subsequent studies have been contradictory. We report the results of a study of the relationship between
BMP2 genotypes and BMD, annual change in BMD, and risk of fracture in male subjects. Materials and Methods. We tested
three single-nucleotide polymorphisms (SNPs) across the BMP2 gene, including Ser37Ala SNP, in 342 Caucasian Englishmen,
comprising 224 control and 118 osteoporotic subjects. Results. BMP2 SNP1 (Ser37Ala) genotypes were found to have similar
low frequency in control subjects and men with osteoporosis. The major informative polymorphism, BMP2 SNP3 (Arg190Ser),
showed no statistically significant association with weight, height, BMD, change in BMD at hip or lumbar spine, and risk of
fracture. Conclusion. There were no genotypic or haplotypic effects of the BMP2 candidate gene on BMD, change in BMD, or
fracture risk identified in this cohort.
1. Introduction
Osteoporosis is primarily a disease of older people and
advancing age is one of the main determinants of osteoporo-
sis and fragility fractures. The estimated lifetime risk of hip,
spine, or distal forearm fracture for Caucasian man at the age
of 50 years is 20% and approximately 30% of all hip fractures
occur in men [1]. Heredity is now generally accepted as
playing an important part in the pathogenesis of osteoporosis
in both men and women. Indeed, after excluding secondary
risk factors and age then the other main causal factor for
osteoporosis in men is genetic [2]. This view is supported
by genetic epidemiological studies on BMD, an important
surrogate of fracture risk, which show that peak bone density
has a substantial heritable component [3]. Variation in BMD
is determined by multiple genes; objective evidence for this
is provided by candidate gene SNP studies, as well as quan-
titative trait locus (QTL) studies in inbred animals and hu-
mans [3]. QTL studies have identified multiple chromosomal
regions which influence bone mass and are linked to osteop-
orosis-related phenotypes.
Studies of classical and novel candidate genes have only
been able to account for a small proportion of the variance in
bone mass. Candidate gene contributions to bone mass also
show gender, geographic, and ethnic variability. Therefore,
studies aimed at identifying the contribution of specific genes
towards BMD and the heritable component to osteoporo-
sis should ideally be gender and ethnic specific. One such
candidate gene is bone morphogenetic protein 2 (BMP2),
located on chromosome 20p12.3. It is a growth factor that
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possesses osteoinductive properties and promotes osteoblast
differentiation and bone formation [4–9]. Linkage analysis
in extended families with osteoporosis in Iceland, using a
phenotype that combines osteoporotic fractures and BMD
measurements, showed linkage to chromosome 20p12.3 [4].
Three variants in the BMP2 gene, a missense polymorphism,
and two anonymous single nucleotide polymorphisms and
the resultant haplotypes have been associated with an osteo-
porotic phenotype, including osteoporotic fractures as well
as low BMD, both before and after the menopause. A number
of follow-up studies however have yielded inconsistent
results [5–9]. To date no investigation has been performed
in an exclusively male cohort and no follow-up study has
investigated the association with risk of osteoporosis in men
and rate of bone loss. In view of the inconclusive nature
of the earlier study and to determine possible gender and
geography-related variability, we therefore investigated the
association of Ser37Ala and Arg190Ser genotypes/haplotypes
with BMD, rate of bone loss, and fracture risk in men from
the UK.
2. Materials and Methods
2.1. Participants. Participants comprised 342 male subjects,
224 controls, and 118 subjects with osteoporosis, who were
all Caucasian men from England, UK [10–12]. The men with
osteoporosis comprised men who had a BMD T score below
−2.5 at either the femoral neck or lumbar spine or had a
low trauma fracture and a T score below −1.0 at either the
femoral neck or lumbar spine. Of the patients 89 also had
a history of fractures (46 had distal forearm fracture, 33
symptomatic vertebral, 6 hip, and 4 other fractures). Their
fractures had all occurred at least six months prior to their
inclusion in the study, and all blood samples were taken
before the initiation of therapy. Underlying secondary causes
of osteoporosis were excluded by medical history, physical
examination, and laboratory investigations. Controls were all
volunteers without any history of low trauma fractures [10].
The laboratory investigations included full blood count, ESR,
biochemical profile, thyroid function tests, serum testos-
terone, sex-hormone-binding globulin, gonadotrophins, and
serum and urine electrophoresis [12].
In a subset of 145 control subjects, there was a follow-
up BMD estimation and annual change in BMD was deter-
mined, in order to test the association between BMP2 geno-
types and change in BMD. A similar analysis of the annual
change in the BMD measurement was not performed in the
men with osteoporosis, because of the confounding effect of
antiresorptive treatment.
2.2. Biochemical and BMD Measurements. Serum testos-
terone, sex-hormone-binding globulins, follicular stimulat-
ing hormone, and luteinizing hormone were measured by
commercially available radioimmunoassay (SAS laboratory,
Royal Victoria Infirmary, Newcastle upon Tyne).
All bone density measurements, for both the osteoporo-
tic and control subjects, were performed by DXA using a
Hologic QDR 2000 Bone Densitometer (Hologic, Waltham,
Mass). In vivo precision for measurement with this system is
1.0% at the lumbar spine (L1–L4) and 1.5% for the femoral
neck. BMD results were obtained as an areal density in g/cm2,
but were also given as T and Z scores. The T score is the
number of standard deviation units above or below the mean
for normal young men, whilst the Z score is the number
of standard deviation units above or below the age-related
normal men (calculated using the manufacturer’s standard
normal reference database).
2.3. BMP2 Genotyping. Three BMP2 SNPs previously iden-
tified were genotyped [4]. Individual PCR standardisation
reactions were set up prior to setting up multiplex PCR
for the three BMP2 SNPs. The three BMP2 SNP poly-
morphisms (SNP1, Ser37Ala; SNP2, Ala94Ser and SNP3,
Arg190Ser) studied are shown in the schematic diagram
(Figure 1). The multiplex reactions were transferred into 384
well plates and treated with shrimp alkaline phosphatase to
remove the excess dNTPs in the reaction mixture. Extension
primers designed to detect the three BMP2 SNPs were added
to the samples and incubated as a PCR reaction for 2 h.
Salt ions were removed from the reaction mixture using a
desalting resin and finally resuspended with 16 µL ddH2O.
15 nL of each sample was spotted onto the chip and analysed
on the Sequenom (Maldi-TOF mass spectrometer). The
results were collected by Spectroanalyser software and the
SNP information, represented by chromatogram peaks at G,
T, A, GT, or AT, was sorted by the Typeranalyser software.
The SNP information was then exported along with the
sample details into MS-Excel file(s) for further statistical
analysis.
2.4. Data Analysis. Results are presented as mean± standard
deviation. Data were analyzed using appropriate statistical
packages (Microsoft Excel XL, SPSS); the significance of
differences in genotype and allele frequency between control
subjects and men with vertebral fractures was determined
using odds ratio and χ2 tests. ANOVA and Student’s unpaired
t-test were used to determine significant differences in BMD
and anthropometric measurements between different BMP2
genotypes and between control subjects and osteoporotic
men, respectively. Genetic association analyses were carried
out using an online HWE calculator (http://ihg.gsf.de/cgi-
bin/hw/hwa1.pl) and SNPSTATS programme (http://bioinfo
.iconcologia.net/SNPstats) which also worked out the Hardy-
Weinberg equilibrium statistics. The haplotypes and associ-
ated statistics were derived from SNPSTATS programme. The
binary logistic regression analyses were performed (SPSS,
version 13.0) with disease or fracture outcome as the depen-
dent variables. The genotypes as categorical variables were
used as specific genotypes; the other variables included in
the regression analysis were age, height, weight, BMI, and key
relevant biochemical parameters.
3. Results
The age, anthropometric, and BMD measurements for the
men with osteoporosis and the control subjects are given in
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Exon 1 Exon 2 Exon 3
SNP1 SNP2 SNP3
BMP2
1. SNP1: nt16 T/G (Ser37Ala)
2. SNP2 : nt287 G/T (Ala94Ser)
3. SNP3: nt224 A/T (Arg190Ser)
Figure 1: Schematic diagram of the three single nucleotide poly-
morphisms in BMP2 gene.
Table 1. The men with osteoporosis, who had age range of
30 to 86 yr, were on average 6 years younger than controls
with the age range of 41 to 79 yr. For this reason when
comparing bone density comparisons, to compensate for
age-related decline in BMD, comparison with Z score was
performed. The osteoporotic patients were also significantly
shorter and lighter than the male control subjects, as well
as having significantly lower BMD at the lumbar spine, total
femoral and femoral neck (P < 0.0001).
3.1. Genotype and Allele Frequency. In both men with osteo-
porosis and control subjects the BMP2 gene SNP1 GG
genotype was absent, and in the combined cohort only eight
subjects were found to be heterozygotes, thus making this
locus uninformative. SNP1 genotype, due to Ser37Ala vari-
ants that change a conserved amino acid, has been previously
shown to have significant association with osteoporosis in
both Danish and Icelandic cohorts [9]. However, in our
cohorts the frequency of SNP1-related G allele was low
in both the patients (0.004) and controls (0.015). SNP2,
which gives rise to Ala to Ser change at 94th position, was
rare, uninformative, and monomorphic, and of the three
genotypes GG, GT, and TT, only GG was observed. SNP3
(Arg190Ser) was polymorphic, and distribution of genotypes
and allele frequencies in both male controls and men
with osteoporosis is shown in Table 2. In both cohorts the
genotypes were in Hardy-Weinberg equilibrium. Genotype
AA was slightly higher in controls (14.3% versus 10.2%,
P = 0.36) while susceptibility genotype TT was higher in
patients (38.1% versus 31.7%, P = 0.28). The odds ratio
for BMP2 SNP3 genotypes and alleles ∗A and ∗T showed no
statistically significant evidence of association with the risk
of osteoporosis, although a trend towards carriers of the ∗T
allele may be worth exploring.
Linkage disequilibrium (LD) was calculated for SNP1
and SNP3 using EM method. The D′ prime is 0.989 (P
value = 0.0264), suggesting that there is a significant linkage
disequilibrium between SNP1 and SNP3, but caution is
warranted in view of the relatively small numbers and low
allele frequencies especially at SNP1 locus which led to a
low r2 value (0.02). Haplotype analysis based on two SNPs
(SNP1 and SNP3) showed that two common haplotypes
(TA and TT) accounted for >99% of the alleles at these
BMP2 loci (Table 3). Haplotype-based association analysis
indicated higher odds ratio for T-T haplotype; however, it
was nonsignificant (OR = 1.43, CI 0.96–2.15, P = 0.08).
Table 1: Age, weight, height and bone mineral density of control
male subjects and men with osteoporosis.
Controls (n = 224) Patients (n = 118)
Age (yr) 65.0 (7.7) 59.1 (12.6)∗∗∗
Height (cm) 173 (6) 171 (8)∗
Weight (kg) 81.5 (10.8) 75.9 (14.6)∗∗∗
Spinal BMD (g/cm2) 1.113 (0.160) 0.797 (0.100)∗∗∗
Spinal Z score 0.96 (1.49) −2.06 (0.96)∗∗∗
Spinal T-score 0.14 (1.46) −2.69 (0.90)∗∗∗
Total femoral BMD
(g/cm2)
1.02 (0.13) 0.783 (0.099)∗∗∗
Total femoral Z score 0.71 (0.96) −1.25 (0.81)∗∗∗
Total femoral T-score −0.32 (0.98) −2.18 (0.75)∗∗∗
Femoral neck BMD
(g/cm2)
0.85 (0.12) 0.692 (0.100)∗∗∗
Femoral neck Z score 0.71 (1.09) −1.05 (0.90)∗∗∗
Femoral neck T score −1.11 (1.09) −2.57 (0.86)∗∗∗
∗
P < 0.01 and ∗∗∗P < 0.0001 using unpaired Student’s t-test.
Table 2: The distribution of BMP2 SNP3 genotype and allele fre-
quencies and odds ratio.
(a)
Genotypes Patients (n, %) Controls (n, %)
AA 12 (10.2) 32 (14.3)
AT 61 (51.7) 121 (54.0)
TT 45 (38.1) 71 (31.7)
Total 118 224
HWE P value 0.19 0.09
Alleles
∗A 0.36 (±0.029) 0.41 (±0.022)
∗T 0.64 0.59
(b)
Allele/genotype
Odd ratios (95% confidence interval),
P value
∗A versus ∗T 1.25 (0.90–1.73) P = 0.18
AA versus AT 1.34 (0.65–2.79), P = 0.43
AA versus TT 1.69 (0.79–3.62), P = 0.17
AA versus AT + TT 1.47 (0.73–2.98), P = 0.28
Armitage’s trend test 1.29, P = 0.15
3.2. BMP2 Genotype Association with Phenotype. The effect
of BMP2 gene SNP3 genotypes on weight, height, and BMD
at lumbar spine, femoral neck, and total femoral was
analysed by ANOVA in both the male controls and men with
osteoporosis, and genotype was found to lack any significant
association (Table 4). The analysis of the pooled data,
comprising controls and patients, also failed to demonstrate
any significant association of SNP3 genotype with the BMD
or anthropometric indices (data not shown).
3.3. Logistic Regression Analysis. The association of the SNP3
genotype was also determined by employing a binary logistic
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Table 3: Basic haplotypes of SNP1 and SNP3 at BMP2 gene in men with osteoporosis and controls.
Haplotype Cases no., freq. Control no., freq. Odds ratio Chi P value
T-A 0.344 0.431 0.69 (0.46–1.04) 3.16 0.07
T-T 0.651 0.565 1.43 (0.96–2.15) 3.09 0.08
G-A 0.00 0.004 0.809 0.36
G-T 0.005 0.000 19.01 (19.01–65938)∗ 0.984 0.321
D′ prime is 0.989 (P value = 0.0264) suggesting that there is a significant linkage disequilibrium between SNP1 and SNP3 but caution is warranted as numbers
are small.
∗This range is due to the small numbers involved.
Table 4: BMP2 SNP3 genotypes and age, weight, height, BMD and annualised bone loss in male controls and men with osteoporosis.
Control Control Control Patients Patients Patients
AA (n = 32) AT (n = 121) TT (n = 71) AA (n = 12) AT (n = 61) TT (n = 45)
Age (yr) 66.1 (7.2) 64.0 (9.4) 65.4 (7.4) 65.7 (9.2) 59.0 (12.6) 57.1 (12.9)
Height (cm) 173 (7) 173 (7) 172 (5) 174 (9) 172 (8) 171 (7)
Weight (kg) 81.9 (9.6) 80.8 (12.4) 81.2 (12.5) 83.9 (25.9) 75.7 (11.8) 74.0 (14)
Spinal BMD (g/cm2) 1.132 (0.195) 1.112 (0.156) 1.105 (0.152) 0.826 (0.058) 0.785 (0.095) 0.807 (0.113)
Spinal Z score 1.15 (1.85) 0.92 (1.46) 0.93 (1.38) −1.71 (0.55) −2.16 (0.88) −2.03 (1.13)
Spinal T score 0.14 (1.46) 0.14 (1.46) 0.14 (1.46) −2.43 (0.50) −2.81 (0.86) −2.60 (1.03)
Total femoral BMD (g/cm2) 1.012 (0.133) 1.014 (0.119) 1.039 (0.135) 0.821 (0.121) 0.782 (0.091) 0.773 (0.114)
Total femoral Z score 0.65 (1.04) 0.64 (0.90) 0.86 (1.01) −0.91 (0.77) −1.24 (0.79) −1.39 (0.87)
Total femoral T score −0.39 (1.03) −0.37 (0.93) −0.21 (1.05) −1.91 (0.95) −2.19 (0.68) −2.28 (0.83)
Femoral neck BMD (g/cm2) 0.860 (0.132) 0.840 (0.132) 0.861 (0.125) 0.708 (0.095) 0.687 (0.087) 0.695 (0.114)
Femoral neck Z score 0.82 (1.24) 0.59 (1.03) 0.85 (1.10) −0.74 (0.67) −1.07 (0.87) −1.10 (1.00)
Femoral neck T score −0.39 (1.03) −0.37 (0.93) −0.20 (1.05) −2.42 (0.87) −2.62 (.076) −2.54 (1.00)
Spinal bone loss (% per annum)
−0.37 (1.14) −0.51 (1.47) −0.45 (1.05)
(n = 20) (n = 69) (n = 56)
Femoral neck bone loss (% per annum)
−0.03 (1.77) 0.20 (1.59) 0.33 (1.42)
(n = 20) (n = 69) (n = 56)
Total femoral bone loss (% per annum)
0.00 (0.80) 0.16 (1.70) 0.15 (1.07)
(n = 20) (n = 69) (n = 56)
No significant effect of BMP2 genotypes on height, weight or BMD was seen using ANOVA (P < 0.05). Annualized loss was studied in a subgroups of subjects,
the numbers indicated in appropriate cells. Results are given as mean, and SDs are given in parentheses.
regression model, which accounted for between 44.5% and
62.6% of the variance in disease status and the overall model
successfully predicted 72% of osteoporotic cases correctly
(Table 5). An analysis of fracture incidence with reference to
genotypes and age, age at fracture, and biochemical param-
eters was performed. Age at fracture, weight, biochemical
parameters, and genotypes did not show any interaction or
independent effect in the fracture prediction. The haplotype
analysis did not reveal any significant influence on BMD
via logistic regression. The addition of covariates to the
model resulted in very sparse data categories and led to wide
confidence intervals.
4. Discussion
This investigation is the only one from the UK that has
sought an association between BMP2 gene polymorphisms
and BMD and susceptibility to osteoporosis. As far as we
know this is the first such investigation carried out exclusively
in men with idiopathic osteoporosis. However, the power of
this study is low; therefore any conclusions drawn should
be treated with caution. Post hoc power analysis, calculated
using a Quanto programme and based on observed allele fre-
quencies, sample size, and odds ratios, showed that the study
had 67% power to detect an odds ratio of 1.50 (moderate
level) and above. In order to achieve an odds ratio of 1.25 one
would require a case-control sample size of 507 individuals in
each group. In the original Icelandic study a significant effect
of BMP2 gene SNP1 polymorphism, Ser37Ala, was demon-
strated in a cohort of 201 subjects, comprising 153 controls
and 58 subjects with fracture [4]. Just like the earlier observa-
tion we too found it to be a rare variant in our cohort with an
allele frequency of 1.25% for Ala37. In previous reports, the
allele frequency for Ala37 in the Icelandic cohort was 0.8% in
controls and 3% to 4.9% in osteoporotic patients and 2.5% in
the Rotterdam study. However, unlike the Icelandic study, we
did not see a significant association or increase in the relative
risk (RR) with the SNP1 genotype. In our cohort we did not
see any GT or TT genotypes of the rare variant of the SNP2
genotype that arises from Ala94Ser. The gene frequency for
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Table 5: Logistic analysis of BMP2 SNP2 genotypes.
B S.E. Wald df Sig. Exp(B)
95.0% C.I. for Exp(B)
Lower Upper
AGE −.069 .021 10.994 1 .001 .933 .896 .972
HT −.054 .171 .101 1 .751 .947 .677 1.325
WT −.944 16.025 .003 1 .953 .389 .000 2.0E + 13
BMI .166 .539 .095 1 .758 1.181 .410 3.398
FNBMD −3.359 2.205 2.319 1 .128 .035 .000 2.622
Spinal BMD −20.656 2.929 49.731 1 .000 .000 .000 .000
SNP3 (AA-Ref) 1.213 2 .545
SNP3 (AT) −.518 .654 .626 1 .429 .596 .165 2.148
SNP3 (TT) −.039 .697 .003 1 .955 .961 .245 3.770
Constant 26.453 27.867 .901 1 .342 2.0E + 11
SNP3 polymorphism, due to Arg190Ser variants, constitut-
ing three genotypes, TT (Arg190Arg), AT (Arg190Ser), and
AA (Ser190Ser), was akin to earlier reports in European
populations. In both male controls and men with osteoporo-
sis the genotypes were in Hardy-Weinberg equilibrium. In
addition to studying the association of the BMP2 to risk of
fracture and BMD, in a subset of subjects we also investigated
the association of the genotype with annual bone loss at
the lumbar spine, total femoral, and femoral neck. Both
initial BMD as well as annual change in the BMD showed
no association with the BMP2 genotype. This could be partly
due to allele frequency differences in different geographical
and gender cohorts. In our study we observed a higher fre-
quency of susceptible T (Ser) allele (64% in patients and 59%
in controls) which is comparable to HAPMAP frequencies
(58%–73% in European populations), but other populations
like Turkish, Korean, and African populations show a lower
frequency [13–15].
The desirability of having a large cohort for SNP studies
investigating polygenic disease association with putative can-
didate genes with phenotype or disease state is well estab-
lished. This is due to the fact that in a polygenic disorder like
osteoporosis many genes make a small, but significant con-
tribution towards the attainment and maintenance of BMD.
Therefore, many genes may be involved in the pathogenesis
of osteoporosis and risk of osteoporotic fractures. In view
of this small contribution of a large number of genes, the
contribution of the genotypic influence is likely to be more
clearly demonstrated in a sufficiently large cohort with the
required level of statistical power. It is, however, becoming
increasingly evident that the association of a large number of
candidate gene SNPs with BMD and osteoporosis risk shows
race-, geography- and gender-related differences [3, 16, 17].
We would also contend that, if a given genotype does make a
substantial contribution to the attainment and maintenance
of BMD and pathophysiology of disease then it should
be possible to demonstrate such effects even in smaller
homogenous cohorts. Indeed, in the original study on BMP2
the genotype association with osteoporosis was established in
a small cohort [4]. We have been able to demonstrate associ-
ations of some novel genotypes in smaller cohorts and which
were subsequently verified in much larger studies [5, 18, 19].
There have been only a handful of studies following the
first report of bone morphogenetic protein 2 (BMP2) as a
susceptibility gene for osteoporotic fractures and low BMD
in Icelandic and Danish populations [9]. Even these relatively
few studies of polymorphisms, within the BMP2 gene in
relation to bone mineral density (BMD) and fracture, have
produced inconsistent findings [4–9]. Neither a Rotterdam
study of a large population-based cohort of Dutch whites
nor a study in healthy American whites could find any con-
tribution to BMD by variations in BMP2 genotypes [7, 8].
On the other hand, a SNP- and haplotype-based US family
study showed highly suggestive associations with BMP2 [5].
In another analysis on a European cohort, variation in BMP2
genotype showed no association with BMD; it did, however,
find a role in aspects of bone quality, which may be age
and site dependent [9]. The 3′ region of the gene was sig-
nificantly associated with the ultrasound parameters speed
of sound and stiffness. Similarly in Turkish women study
BMP2 polymorphisms did not substantially contribute to
lumbar spine bone mineral density [14]. Overall, association
studies have shown that Arg190Ser SNP is not associated
with BMD in different populations and the initial study
may have been a false positive association. Alternatively, it
is entirely possible that the association may show gender-
related variation, as the initial study had shown association in
females and our study was carried out in an exclusively male
population.
In conclusion, in a BMP2 candidate gene polymorphism
study in the UK, comprising osteoporotic men and male con-
trol subjects, there were no genotypic or haplotypic effects on
phenotype and fracture risk identified.
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